Literature DB >> 24596498

Recombinant expression and purification of human placental growth factor 1 and specific camel heavy chain polyclonal antibody preparation.

Roghaye Arezumand1, Reza Mahdian1, Mahdi Behdani2, Hossein Khanahmad3, Jahangir Langari1, Nabiollah Namvarasl4, Reza Hassanzadeh-Ghasabeh5, Sirous Zeinali1.   

Abstract

Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family. Unlike VEGF, PlGF is dispensable for normal cell development as well as playing various roles in pathological angiogenesis which occurs in tissue ischemia, inflammation, and malignancy. The PlGF-1 has been considered as a potential candidate for the diagnosis and targeting of pathological angiogenesis. Camelidae serum contains an important fraction of functional antibodies, called heavy-chain antibodies (HcAbs) that are naturally devoid of light chains. Camelid HcAbs recognize their cognate antigens by a single variable-domain, referred to as VHH or Nanobody. Here, we describe the expression and purification of recombinant human PlGF-1 (rhPlGF-1). This protein was subsequently used for the preparation of camel heavy chain polyclonal antibody against rhPlGF-1. The recombinant expression plasmid pET-26b-hPlGF-1 was introduced into Escherichia coli BL21 cells to express the rhPlGF-1 protein. Purified rhPlGF-1 was used to immunize camel, the specific reactivity of HcAb was determined with ELISA and western blot. Western blot analysis indicated that the antiserum specifically reacted to the recombinant protein. The rhPlGF-1 protein and its antibody may be used for the development of detection assays needed for clinical research.

Entities:  

Keywords:  Angiogenesis; Heavy chain antibody; PlGF; Polyclonal antibody; VHH

Year:  2013        PMID: 24596498      PMCID: PMC3937466          DOI: 10.1016/j.sjbs.2013.04.008

Source DB:  PubMed          Journal:  Saudi J Biol Sci        ISSN: 2213-7106            Impact factor:   4.219


  16 in total

Review 1.  Snake antivenoms.

Authors:  David G Lalloo; R David G Theakston
Journal:  J Toxicol Clin Toxicol       Date:  2003

Review 2.  The controversial role of placental growth factor in tumor growth.

Authors:  Domenico Ribatti
Journal:  Cancer Lett       Date:  2011-03-22       Impact factor: 8.679

Review 3.  Biology of vascular endothelial growth factors.

Authors:  Himadri Roy; Shalini Bhardwaj; Seppo Ylä-Herttuala
Journal:  FEBS Lett       Date:  2006-04-17       Impact factor: 4.124

4.  Camelid immunoglobulins and nanobody technology.

Authors:  S Muyldermans; T N Baral; V Cortez Retamozzo; P De Baetselier; E De Genst; J Kinne; H Leonhardt; S Magez; V K Nguyen; H Revets; U Rothbauer; B Stijlemans; S Tillib; U Wernery; L Wyns; Gh Hassanzadeh-Ghassabeh; D Saerens
Journal:  Vet Immunol Immunopathol       Date:  2008-10-17       Impact factor: 2.046

Review 5.  Tumor angiogenesis and novel antiangiogenic strategies.

Authors:  Michael S Gordon; David S Mendelson; Gerry Kato
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

6.  Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment.

Authors:  Ruth C Ladenson; Dan L Crimmins; Yvonne Landt; Jack H Ladenson
Journal:  Anal Chem       Date:  2006-07-01       Impact factor: 6.986

7.  Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama.

Authors:  R van der Linden; B de Geus; W Stok; W Bos; D van Wassenaar; T Verrips; L Frenken
Journal:  J Immunol Methods       Date:  2000-06-23       Impact factor: 2.303

Review 8.  Nanobody; an old concept and new vehicle for immunotargeting.

Authors:  Fatemeh Rahbarizadeh; Davoud Ahmadvand; Zahra Sharifzadeh
Journal:  Immunol Invest       Date:  2011-01-11       Impact factor: 3.657

Review 9.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 10.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Authors:  Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

View more
  6 in total

1.  Characterization of a new cry2Ab gene of Bacillus thuringiensis with high insecticidal activity against Plutella xylostella L.

Authors:  Zhizhen Pan; Lian Xu; Yujing Zhu; Huai Shi; Zheng Chen; Meichun Chen; Qingxi Chen; Bo Liu
Journal:  World J Microbiol Biotechnol       Date:  2014-06-19       Impact factor: 3.312

2.  Preparation of goat and rabbit anti-camel immunoglobulin G whole molecule labeled with horseradish peroxidase.

Authors:  Eman Hussein Abdel-Rahman; Jakeen Kamal El-Jakee; Mahmoud Essam Hatem; Nagwa Sayed Ata; Ehab Ali Fouad
Journal:  Vet World       Date:  2017-01-23

3.  Cloning, expression and purification of a polytopic antigen comprising of surface antigens of Toxoplasma gondii.

Authors:  Abbas Alibakhshi; Mojgan Bandehpour; Bahram Kazemi
Journal:  Iran J Microbiol       Date:  2017-08

Review 4.  Antibody variable region engineering for improving cancer immunotherapy.

Authors:  Hantao Lou; Xuetao Cao
Journal:  Cancer Commun (Lond)       Date:  2022-07-13

5.  Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector.

Authors:  Alfiah Noor; Gudrun Walser; Matthijs Wesseling; Philippe Giron; Albert-Menno Laffra; Fatima Haddouchi; Jacques De Grève; Peter Kronenberger
Journal:  BMC Res Notes       Date:  2018-10-22

6.  Expressing of Recombinant VEGFR2-specific Nanobody in Baculovirus Expression System.

Authors:  Narjes Shokrollahi; Mahdi Habibi-Anbouhi; Ali Jahanian-Najafabadi; Ehsan Alirahimi; Mahdi Behdani
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.